Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Personalized disease prediction and prevention in chronic inflammatory disorders

Project description

Early detection and treatment of chronic inflammatory diseases

Chronic inflammatory diseases (CIDs), including rheumatoid arthritis and inflammatory bowel diseases, affect over 10 % of the EU population, placing a burden on healthcare systems. These conditions often progress from pre-symptomatic stages, with high unmet medical needs for early detection and intervention. With this in mind, the EU-funded PerPrev-CID project will develop decision support tools for preventive and early therapeutic interventions. Key objectives include identifying predictive markers for disease progression, creating digital health tools for continuous patient monitoring, and exploring the impact of nutrition on disease outcomes. Ultimately, the project seeks to enhance patient outcomes, reduce disease burden, and empower EU citizens through AI-driven, privacy-preserving solutions.

Objective

Background: Chronic inflammatory diseases (CID) are a group of non-communicable disorders of the immune system with a lifetime prevalence of over 10% in the EU. Rheumatoid arthritis (RA) and inflammatory bowel diseases (IBD) are two archetypal CIDs with a particularly high unmet medical need and impact on European health care systems.
Objectives: The PerPrev-CID consortium aims to set up new standards for decision support tool development for preventive and early therapeutic interventions in RA and IBD.
Selected main aims are: (i) To define actionable predictors from longitudinal multi-level Omics and clinical data integration In RA and IBD. We will identify markers indicating progression from pre-symptomatic to manifest disease and signatures predicting early disease relapse (ii) To develop new tools for home-based and continuous assessment of patient-related data dimensions using digital health apps/wearables, including more innovative, objective parameters, such as movement patterns, physical activity, and sleep. (iii) To assess the health-promoting effects of interfering with the tryptophan pathway in a proof-of-concept nutritional study in early RA and IBD. (iv) To study ethical, legal and economic consequences of risk assessment and early low-threshold preventive interventions. Important aspects are the communication of the risk concept, economic implications of broad testing and interventions as well as patients´ perception of the concept of risk prediction.
Expected impact: We will develop prototype solutions for privacy-preserving AI-based data analysis for research and clinical application and will test a first proof-of-concept low threshold intervention in RA and IBD. Our approaches will provide a clear health benefit to the citizens of the EU by improving health outcomes, empowering joint decision making and contributing to appropriate action plans to reduce the avoidable burden of the diseases.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2024-STAYHLTH-01-two-stage

See all projects funded under this call

Coordinator

UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN
Net EU contribution
€ 3 161 769,60
Address
Ratzeburger Allee 160
23562 Lübeck
Germany
Region
Schleswig-Holstein Schleswig-Holstein Lübeck, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Participants (12)

Partners (2)